Therapeutic complement inhibition: new developments
Activation of the complement system significantly contributes to the pathogenesis of various acute and chronic inflammatory diseases. Current strategies to inhibit complement include the replacement or substitution of endogenous soluble complement inhibitors (e.g., C1 inhibitor [C1 inh], recombinant...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2010
|
| In: |
Seminars in thrombosis and hemostasis
Year: 2010, Volume: 36, Issue: 6, Pages: 660-668 |
| ISSN: | 1098-9064 |
| DOI: | 10.1055/s-0030-1262888 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: http://dx.doi.org/10.1055/s-0030-1262888 Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0030-1262888 
|
| Author Notes: | Woodruff Emlen, Wenhan Li, and Michael Kirschfink |
| Summary: | Activation of the complement system significantly contributes to the pathogenesis of various acute and chronic inflammatory diseases. Current strategies to inhibit complement include the replacement or substitution of endogenous soluble complement inhibitors (e.g., C1 inhibitor [C1 inh], recombinant soluble complement receptor 1, TP10), the administration of antibodies to block key proteins of the cascade reaction (e.g., C5) or to neutralize the action of the complement-derived anaphylatoxins, or blockade of complement receptors (e.g., C5aR, CD88). The recent approvals of anti-C5 for the treatment of paroxysmal nocturnal hemoglobinuria as well as of C1 inh for the treatment of hereditary angioedema beyond European countries have provided a resurgence of interest in the potential of complement therapeutics for the treatment of disease. |
|---|---|
| Item Description: | Gesehen am 18.06.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1098-9064 |
| DOI: | 10.1055/s-0030-1262888 |